1stOncology™: Cancer Intelligence Service – Page 7806 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Scorpion Therapeutics to Present Mutant-Selective PI3Kα Program at AACR Annual Meeting 2022

On March 8, 2022 Scorpion Therapeutics, Inc. ("Scorpion Therapeutics"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, reported that it will share preclinical proof-of-concept data for STX-H1047-PI3Kα, its lead program targeting the H1047X-mutant form of phosphoinositide 3-kinase alpha ("PI3Kα"), in a late-breaking poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2022 in New Orleans, Louisiana, taking place April 8 – 13, 2022 (Press release, Scorpion Therapeutics, MAR 8, 2022, View Source [SID1234609707]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"We are excited to present preclinical data demonstrating the potentially best-in-class profile of our lead program, STX-H1047-PI3Kα. PI3Kα is an established cancer target and one of the most highly mutated targets in cancer. However, approved therapeutic options are limited by significant metabolic side effects and an inability to treat tumors that have progressed into the central nervous system," said Axel Hoos, M.D., Ph.D., CEO of Scorpion Therapeutics. "Consistent with our Precision Oncology 2.0 strategy, we designed STX-H1047-PI3Kα to specifically address these limitations, in hopes of delivering safer and more effective medicines to patients living with certain solid tumors. We look forward to informing the oncology community of our progress during AACR (Free AACR Whitepaper), as we work towards submitting an investigational new drug application for STX-H1047-PI3Kα in 2023."

Details of the poster presentation are as follows:

Presentation Title: Discovery and Characterization of a Mutant Selective PI3KαH1047X Inhibitor with a Best-In-Class Profile
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Abstract Number: LB194
Poster Board Number: 7
Date & Time: Wednesday, Apr 13, 2022 at 9:00 a.m. – 12:30 p.m. CT (10:00 a.m. – 1:30 p.m. ET)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 16

The abstract and poster presentation will be published online at 12:00 p.m. CT (1:00 p.m. ET) on April 8, 2022 on the AACR (Free AACR Whitepaper) website at www.aacr.org.

MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

On March 8, 2022 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 to be held April 8 – 13, 2022 (Press release, MEI Pharma, MAR 8, 2022, View Source [SID1234609706]).

Details of the poster presentations:

Title: Efficacy and immune profiling of the PI3K delta inhibitor zandelisib (ME-401) in a preclinical model of chronic lymphocytic leukemia (CLL)
Authors: Dr. Maharaj, et. al.
Date: Friday, April 8, 2022, 8:30 AM ET
Abstract ID: 5496

Summary of results: data from preclinical studies with zandelisib ex vivo in normal human T cells and in vivo in a murine CLL model suggest that zandelisib has immunomodulatory properties on human T cells including decreased activation and expression of suppressive markers such as PD-1 and CTLA-4 on inducible regulatory (Tregs) and CD4+ T cells. In the murine CLL model, a reduction in Treg numbers, markers of terminal memory differentiation and T-cell exhaustion on CD4+ and CD8+ T cells, as well as improvement in overall survival was observed.

Title: ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML
Authors: Katie Hurrish, et. al.
Date: Wednesday, April 13, 2022, 10:00 AM – 1:30 PM ET
Abstract ID: 3785

Summary of results: data from in vitro and in vivo preclinical studies evaluating the combination of ME-344 with venetoclax in standard-of-care-resistant acute myeloid leukemia (AML) cell lines and relapsed or refractory (R/R) AML patient samples suggest that ME-344, both alone and in combination with venetoclax, inhibits purine biosynthesis, suppresses oxidative phosphorylation, induces apoptosis and decreases Mcl-1, which together target metabolic vulnerabilities of AML cells.

Gennao Bio Announces Oral Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting

On March 8, 2022 Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, reported that an abstract reporting preclinical results of its proprietary, non-viral gene monoclonal antibody (GMAB) platform technology has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, taking place April 8 – 13, 2022 in New Orleans, LA (Press release, Gennao Bio, MAR 8, 2022, View Source [SID1234609705]). Gennao’s GMAB platform utilizes a novel, cell-penetrating antibody to non-covalently form complexes with and systemically target and deliver effective levels of nucleic acids, including immune-stimulating synthetic RNA, to solid tumors.

The details of the oral presentation are as follows:

Title: Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibody
Abstract Control Number: 6710
Session Title: Immune Checkpoint and Immune Modulatory Therapy
Session Type: Minisymposium
Session Date and Time: Sunday, April 10, 2022; 3:00 p.m. – 5:00 p.m. Central Daylight Time
Presenter: Elias Quijano, Yale School of Medicine

Sengenics Strengthens Strategy to Enable Wider Access to Patented Protein Microarray Technology with the Launch of the Sengenics i-Ome® Protein Array Kit

On March 8, 2022 Sengenics reported the commercial launch of the i-Ome Protein Array Kit (Press release, Sengenics, MAR 8, 2022, View Source [SID1234609704]). The i-Ome Protein Array Kit contains slide-based, high density protein microarrays, comprised of 1600+ immobilized, full-length, correctly folded human proteins. The new product brings the KREX technology within reach to deliver a best-in-class autoantibody discovery tool and to enable researchers focused on autoantibody biomarker identification in the autoimmune disease, immuno-oncology and neuroinflammation fields.

"The Sengenics i-Ome Protein Array Kit offers greater access to exceptional autoantibody discovery power and operating efficiency, unlocking highly multiplexed applications," said Dr. Arif Anwar, Sengenics CEO. "Bearing in mind our customers’ needs, Sengenics reimagined the kit with innovative solutions that extend the unmatched accuracy and reproducibility of KREX technology to fuel more in-depth research across the autoimmune, immuno-oncology and neurology fields."

DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma,” Published in SKIN: The Journal of Cutaneous Medicine

On March 8, 2022 DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported that SKIN: The Journal of Cutaneous Medicine has published its original research study, with Daniel M. Siegel, MD, MS as the lead author (Press release, DermTech International, MAR 8, 2022, View Source [SID1234609702]). A nationally recognized reimbursement expert, Dr. Siegel is a clinical professor of dermatology at SUNY Downstate Medical Center and a former president of the American Academy of Dermatology. By incorporating the Pigmented Lesion Assay ("PLA") into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma, the study highlights the potential reduction in cost for commercial health insurance plans, in addition to a higher quality of care for patients and improved health outcomes.

The PLA, a component of the DermTech Melanoma Test, objectively measures genomic markers associated with melanoma within skin tissue samples collected via non-invasive adhesive patches, or Smart Stickers. It is used to identify high-risk lesions and help providers determine the next best treatment: either a biopsy and histopathologic evaluation or clinical surveillance of the lesion in question. Comparatively, the traditional care pathway for evaluating suspicious moles is visual assessment, which is subjective, followed by a potentially avoidable surgical biopsy and histopathologic assessment.

The findings outlined in the publication, "Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma," suggests that use of the PLA to rule out melanoma can minimize avoidable surgical procedures on benign lesions and decrease downstream costs of late-stage melanoma diagnoses, which reduces overall cost of care. To determine the per member per month ("PMPM") net savings of incorporating the PLA into the current care pathway, a Return on Investment ("ROI") model was developed from a U.S. payor perspective. This model predicted annual net savings of $0.54 PMPM for commercial health plans over a three-year period with incorporation of the PLA.

"There is a clear need for objective, cost-effective technologies to help improve the assessment, classification and management of skin lesions and moles suspicious for melanoma," said Dr. Siegel. "The PLA offers just that, helping to make sure that the lesions and moles most likely to be malignant are the ones being biopsied."

The published findings in SKIN can be found here: View Source

"This research study is a testament to how the PLA has the potential to reduce costs for health insurance plans and improve patient care by limiting the number of potentially avoidable biopsies," said John Dobak, MD, CEO of DermTech. "As we continue to leverage genomics to advance melanoma detection and dermatology as a whole, we continue to believe that the PLA has the potential to be incorporated into additional insurance plans."